Vascular Biogenics Accounts Payable

Vascular Biogenics (VBLT) currently reports a accounts payable of $1.1M as of June 2024. That compares with $720K in the prior-year period — up 58.8% year over year. Use the charts on this page to explore Vascular Biogenics's accounts payable history and peer comparisons.

Vascular Biogenics's accounts payable increased from $720K to $1.1M — a 58.8% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vascular Biogenics reported $1.1M in accounts payable as of June 2024. That compares with $720K in the prior-year period — up 58.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vascular Biogenics, and consider following VBLT for alerts when major investors trade the stock.

Vascular Biogenics is classified in the Healthcare sector. On accounts payable, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VBLT with unrelated industries.